{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:30:10Z","timestamp":1787574610582,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK 119860"],"award-info":[{"award-number":["R01 DK 119860"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74472-4","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:55:39Z","timestamp":1784577339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-0687","authenticated-orcid":false,"given":"Guangyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-9892","authenticated-orcid":false,"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-3737","authenticated-orcid":false,"given":"Arinc","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8945-5997","authenticated-orcid":false,"given":"Angela","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul K.","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Obuchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amon","family":"Asgharpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-7149","authenticated-orcid":false,"given":"Brian A.","family":"Telfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3244-0994","authenticated-orcid":false,"given":"Theodore T.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-8724","authenticated-orcid":false,"given":"Anthony E.","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"74472_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"74472_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le, M. H. et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach. Clin. Mol. Hepatol. 28, 841 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"74472_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R., Brenner, D. A. et al. Liver fibrosis. J. Clin. Investig. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Investig."},{"key":"74472_CR4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"74472_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hep.23314","volume":"51","author":"C S\u00f6derberg","year":"2010","unstructured":"S\u00f6derberg, C. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595\u2013602 (2010).","journal-title":"Hepatology"},{"key":"74472_CR6","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta, F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin. Gastroenterol. Hepatol. 18, 2324\u20132331 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gtc.2019.09.007","volume":"49","author":"MD Muthiah","year":"2020","unstructured":"Muthiah, M. D. & Sanyal, A. J. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol. Clin. 49, 1\u201323 (2020).","journal-title":"Gastroenterol. Clin."},{"key":"74472_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"74472_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson, J. B. et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 51, 728\u2013736 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"74472_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557\u20131565 (2017).","journal-title":"Hepatology"},{"key":"74472_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148\u20131155 (2015).","journal-title":"J. Hepatol."},{"key":"74472_CR12","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin, M. et al. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin. Gastroenterol. Hepatol. 22, 2367\u20132377 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu, V. et al. NIS2+\u2122 as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. J. Hepatol. 80, 209\u2013219 (2024).","journal-title":"J. Hepatol."},{"key":"74472_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.11.009","volume":"80","author":"JC-T Lai","year":"2024","unstructured":"Lai, J. C.-T. & Wong, V. W.-S. Using NIS2+\u2122 to identify at-risk MASH in clinical trials. J. Hepatol. 80, 181\u2013183 (2024).","journal-title":"J. Hepatol."},{"key":"74472_CR15","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.3748\/wjg.v26.i39.5919","volume":"26","author":"A Campos-Murgu\u00eda","year":"2020","unstructured":"Campos-Murgu\u00eda, A., Ruiz-Marg\u00e1in, A., Gonz\u00e1lez-Regueiro, J. A. & Mac\u00edas-Rodr\u00edguez, R. U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J. Gastroenterol. 26, 5919 (2020).","journal-title":"World J. Gastroenterol."},{"key":"74472_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using fibroscan-based agile scores. J. Hepatol. 78, 247\u2013259 (2023).","journal-title":"J. Hepatol."},{"key":"74472_CR17","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J., Castera, L. & Wong, V. W.-S. Noninvasive assessment of liver fibrosis in NAFLD. Clin. Gastroenterol. Hepatol. 21, 2026\u20132039 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR18","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat. Med. 29, 2656\u20132664 (2023).","journal-title":"Nat. Med."},{"key":"74472_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling, R. K. et al. AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 81, 672\u2013724 (2025).","journal-title":"Hepatology"},{"key":"74472_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJM200102083440610","volume":"344","author":"PA Bonis","year":"2001","unstructured":"Bonis, P. A., Friedman, S. L. & Kaplan, M. M. Is liver fibrosis reversible? N. Engl. J. Med. 344, 452\u2013454 (2001).","journal-title":"N. Engl. J. Med."},{"key":"74472_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","volume":"79","author":"ME Rinella","year":"2024","unstructured":"Rinella, M. E. et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79, 674\u2013689 (2024).","journal-title":"Hepatology"},{"key":"74472_CR22","doi-asserted-by":"crossref","unstructured":"Haghnejad, V., Burke, L., El Ouahabi, S., Parker, R. & Rowe, I. A. Prediction models for liver decompensation in compensated advanced chronic liver disease: a systematic review. Hepatology 83, 530\u2013551 (2026).","DOI":"10.1097\/HEP.0000000000001359"},{"key":"74472_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo, A. A., Sheth, S. G. & Chopra, S. Liver biopsy. N. Engl. J. Med. 344, 495\u2013500 (2001).","journal-title":"N. Engl. J. Med."},{"key":"74472_CR24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C. & Smith, A. D. Liver biopsy. Hepatology 49, 1017\u20131044 (2009).","journal-title":"Hepatology"},{"key":"74472_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterology 20, 475 (2014).","journal-title":"World J. Gastroenterology"},{"key":"74472_CR26","doi-asserted-by":"publisher","first-page":"e0147237","DOI":"10.1371\/journal.pone.0147237","volume":"11","author":"EB Tapper","year":"2016","unstructured":"Tapper, E. B., Hunink, M. M., Afdhal, N. H., Lai, M. & Sengupta, N. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS ONE 11, e0147237 (2016).","journal-title":"PLoS ONE"},{"key":"74472_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C-T Wai","year":"2003","unstructured":"Wai, C.-T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"74472_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"74472_CR29","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera, I. et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin. Gastroenterol. Hepatol. 20, 2567\u20132576 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR30","doi-asserted-by":"publisher","first-page":"e2123923","DOI":"10.1001\/jamanetworkopen.2021.23923","volume":"4","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. et al. Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw. Open 4, e2123923\u2013e2123923 (2021).","journal-title":"JAMA Netw. Open"},{"key":"74472_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 970\u2013985 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"74472_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.crad.2020.01.005","volume":"75","author":"C Fang","year":"2020","unstructured":"Fang, C., Lim, A. & Sidhu, P. Ultrasound-based liver elastography in the assessment of fibrosis. Clin. Radiol. 75, 822\u2013831 (2020).","journal-title":"Clin. Radiol."},{"key":"74472_CR33","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s00330-019-06407-1","volume":"30","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. Eur. Radiol. 30, 1264\u20131273 (2020).","journal-title":"Eur. Radiol."},{"key":"74472_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63095-8","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. A machine learning-based model analysis for serum markers of liver fibrosis in chronic hepatitis B patients. Sci. Rep. 14, 12081 (2024).","journal-title":"Sci. Rep."},{"key":"74472_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/HEP.0000000000000364","volume":"78","author":"J Lee","year":"2023","unstructured":"Lee, J. et al. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: a development and validation study. Hepatology 78, 258\u2013271 (2023).","journal-title":"Hepatology"},{"key":"74472_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06998-8","volume":"12","author":"V Blanes-Vidal","year":"2022","unstructured":"Blanes-Vidal, V., Lindvig, K. P., Thiele, M., Nadimi, E. S. & Krag, A. Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care. Sci. Rep. 12, 2914 (2022).","journal-title":"Sci. Rep."},{"key":"74472_CR37","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/S2589-7500(21)00270-3","volume":"4","author":"SS Sarvestany","year":"2022","unstructured":"Sarvestany, S. S. et al. Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. Lancet Digit. Health 4, e188\u2013e199 (2022).","journal-title":"Lancet Digit. Health"},{"key":"74472_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 48, 835\u2013847 (2008).","journal-title":"J. Hepatol."},{"key":"74472_CR39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1148\/radiol.2015150619","volume":"276","author":"RG Barr","year":"2015","unstructured":"Barr, R. G. et al. Elastography assessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement. Radiology 276, 845\u2013861 (2015).","journal-title":"Radiology"},{"key":"74472_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jmri.23731","volume":"37","author":"SK Venkatesh","year":"2013","unstructured":"Venkatesh, S. K., Yin, M. & Ehman, R. L. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J. Magn. Reson. Imaging 37, 544\u2013555 (2013).","journal-title":"J. Magn. Reson. Imaging"},{"key":"74472_CR41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cgh.2007.06.012","volume":"5","author":"M Yin","year":"2007","unstructured":"Yin, M. et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol. 5, 1207\u20131213 (2007).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR42","doi-asserted-by":"publisher","first-page":"S1379","DOI":"10.14309\/01.ajg.0001037068.07637.b1","volume":"119","author":"B Bentley","year":"2024","unstructured":"Bentley, B., Ventura, F., Obermmiller, C., Russo, M. & Rudnick, S. S1925 limitations of FIB-4 score in excluding advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Off. J. Am. Coll. Gastroenterol. 119, S1379 (2024).","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"74472_CR43","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5009\/gnl19173","volume":"14","author":"E Kaya","year":"2019","unstructured":"Kaya, E. et al. Simple noninvasive scores are clinically useful to exclude, not predict, advanced fibrosis: a study in Turkish patients with biopsy-proven nonalcoholic fatty liver disease. Gut Liver 14, 486 (2019).","journal-title":"Gut Liver"},{"key":"74472_CR44","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"74472_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","volume":"13","author":"EB Tapper","year":"2015","unstructured":"Tapper, E. B., Castera, L. & Afdhal, N. H. FibroScan (vibration-controlled transient elastography): where does it stand in United States practice. Clin. Gastroenterol. Hepatol. 13, 27\u201336 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR46","doi-asserted-by":"publisher","first-page":"e0118432","DOI":"10.1371\/journal.pone.0118432","volume":"10","author":"T Saito","year":"2015","unstructured":"Saito, T. & Rehmsmeier, M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS ONE 10, e0118432 (2015).","journal-title":"PLoS ONE"},{"key":"74472_CR47","doi-asserted-by":"crossref","unstructured":"Davis, J. & Goadrich, M. The relationship between precision-recall and ROC Curves. In Proceedings of the 23rd International Conference on Machine Learning, (eds Cohen, W. W. & Moore, A.) 233\u2013240 (Association for Computing Machinery, 2006).","DOI":"10.1145\/1143844.1143874"},{"key":"74472_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41592-021-01232-1","volume":"18","author":"N Altman","year":"2021","unstructured":"Altman, N. & Krzywinski, M. Graphical assessment of tests and classifiers. Nat. Methods 18, 8 (2021).","journal-title":"Nat. Methods"},{"key":"74472_CR49","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"74472_CR50","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m, H., Vessby, J., Ekstedt, M. & Shang, Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J. Hepatol. 80, e76\u2013e77 (2024).","journal-title":"J. Hepatol."},{"key":"74472_CR51","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.jhepr.2025.101351","volume":"7","author":"J Fichez","year":"2025","unstructured":"Fichez, J. et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic Trials. JHEP Rep. 7, 101351 (2025).","journal-title":"JHEP Rep."},{"key":"74472_CR52","doi-asserted-by":"crossref","unstructured":"Thorhauge, K. H. et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J. Hepatol. 81, 22\u201332 (2024).","DOI":"10.1016\/j.jhep.2024.02.019"},{"key":"74472_CR53","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS Project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"74472_CR54","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.3350\/cmh.2024.0351","volume":"30","author":"HY Kim","year":"2024","unstructured":"Kim, H. Y. et al. Prevalence of clinically significant liver fibrosis in the general population: a systematic review and meta-analysis. Clin. Mol. Hepatol. 30, S199 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"74472_CR55","doi-asserted-by":"publisher","first-page":"e231461","DOI":"10.1148\/radiol.231461","volume":"311","author":"L-D Chen","year":"2024","unstructured":"Chen, L.-D. et al. US-based sequential algorithm integrating an AI model for advanced liver fibrosis screening. Radiology 311, e231461 (2024).","journal-title":"Radiology"},{"key":"74472_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1536867X20909693","volume":"20","author":"J Cook","year":"2020","unstructured":"Cook, J. & Ramadas, V. When to consult precision-recall curves. Stata J. 20, 131\u2013148 (2020).","journal-title":"Stata J."},{"key":"74472_CR57","doi-asserted-by":"publisher","first-page":"e100510","DOI":"10.1136\/bmjhci-2021-100510","volume":"29","author":"O Yasar","year":"2022","unstructured":"Yasar, O. et al. Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). BMJ Health Care Inform. 29, e100510 (2022).","journal-title":"BMJ Health Care Inform."},{"key":"74472_CR58","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jacep.2023.04.008","volume":"9","author":"H Gruwez","year":"2023","unstructured":"Gruwez, H. et al. Detecting paroxysmal atrial fibrillation from an electrocardiogram in sinus rhythm: external validation of the AI approach. Clin. Electrophysiol. 9, 1771\u20131782 (2023).","journal-title":"Clin. Electrophysiol."},{"key":"74472_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1148\/radiol.2020191152","volume":"295","author":"A Han","year":"2020","unstructured":"Han, A. et al. Assessment of hepatic steatosis in nonalcoholic fatty liver disease by using quantitative US. Radiology 295, 106\u2013113 (2020).","journal-title":"Radiology"},{"key":"74472_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30750-5","volume":"13","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Machine learning classifiers for screening nonalcoholic fatty liver disease in general adults. Sci. Rep. 13, 3638 (2023).","journal-title":"Sci. Rep."},{"key":"74472_CR61","doi-asserted-by":"crossref","unstructured":"Harrison, S. A. & Dubourg, J. Liver biopsy evaluation in MASH drug development: think thrice, act wise. J. Hepatol. 81, 886\u2013894 (2024).","DOI":"10.1016\/j.jhep.2024.06.008"},{"key":"74472_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1109\/TCBB.2017.2690848","volume":"15","author":"S Hashem","year":"2017","unstructured":"Hashem, S. et al. Comparison of machine learning approaches for prediction of advanced liver fibrosis in chronic hepatitis C patients. IEEE\/ACM Trans. Comput. Biol. Bioinforma. 15, 861\u2013868 (2018).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinforma."},{"key":"74472_CR63","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","volume":"22","author":"P Nasr","year":"2024","unstructured":"Nasr, P. et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin. Gastroenterol. Hepatol. 22, 1048\u20131057 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR64","doi-asserted-by":"crossref","unstructured":"Almahanna, Y. et al. Natural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort. Ann. Hepatol. 31, 102166 (2026).","DOI":"10.1016\/j.aohep.2025.102166"},{"key":"74472_CR65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ultrasmedbio.2017.01.022","volume":"43","author":"M Dhyani","year":"2017","unstructured":"Dhyani, M. et al. Validation of shear wave elastography cutoff values on the supersonic aixplorer for practical clinical use in liver fibrosis staging. Ultrasound Med. Biol. 43, 1125\u20131133 (2017).","journal-title":"Ultrasound Med. Biol."},{"key":"74472_CR66","unstructured":"Evans, J. D. Straightforward Statistics for the Behavioral Sciences (Thomson Brooks\/Cole Publishing Co, 1996)."},{"key":"74472_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20084-z","volume":"12","author":"F \u212bberg","year":"2022","unstructured":"\u212bberg, F. et al. Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study. Sci. Rep. 12, 15581 (2022).","journal-title":"Sci. Rep."},{"key":"74472_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01774-w","volume":"21","author":"R Ding","year":"2021","unstructured":"Ding, R. et al. Nomogram for predicting advanced liver fibrosis and cirrhosis in patients with chronic liver disease. BMC Gastroenterol. 21, 190 (2021).","journal-title":"BMC Gastroenterol."},{"key":"74472_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Van Buuren","year":"2011","unstructured":"Van Buuren, S. & Groothuis-Oudshoorn, K. MICE: multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"74472_CR70","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67, 1754\u20131767 (2018).","journal-title":"Hepatology"},{"key":"74472_CR71","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1016\/j.cgh.2023.03.032","volume":"21","author":"CM Canivet","year":"2023","unstructured":"Canivet, C. M. et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic nonalcoholic steatohepatitis: an international study with 1924 patients. Clin. Gastroenterol. Hepatol. 21, 3097\u20133106 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74472_CR72","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1002\/sim.5777","volume":"32","author":"H Ma","year":"2013","unstructured":"Ma, H., Bandos, A. I., Rockette, H. E. & Gur, D. On use of partial area under the ROC curve for evaluation of diagnostic performance. Stat. Med. 32, 3449\u20133458 (2013).","journal-title":"Stat. Med."},{"key":"74472_CR73","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","volume":"329","author":"JJ Deeks","year":"2004","unstructured":"Deeks, J. J. & Altman, D. G. Diagnostic tests 4: likelihood ratios. BMJ 329, 168\u2013169 (2004).","journal-title":"BMJ"},{"key":"74472_CR74","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1046\/j.1525-1497.2002.10750.x","volume":"17","author":"S McGee","year":"2002","unstructured":"McGee, S. Simplifying Likelihood Ratios. J. Gen. Intern. Med. 17, 647\u2013650 (2002).","journal-title":"J. Gen. Intern. Med."},{"key":"74472_CR75","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0196-0644(99)70346-X","volume":"33","author":"SR Hayden","year":"1999","unstructured":"Hayden, S. R. & Brown, M. D. Likelihood ratio: a powerful tool for incorporating the results of a diagnostic test into clinical decision making. Ann. Emerg. Med. 33, 575\u2013580 (1999).","journal-title":"Ann. Emerg. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74472-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74472-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:08:29Z","timestamp":1787573309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74472-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74472"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74472-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A provisional patent application related to this work, titled \u2018A Precision-Constrained Risk Stratification Platform\u2019, has been filed by G.Z., X.W., P.G., B.A.T., T.T.P., and A.E.S. A.O. discloses consultancy to SmartAlfa, Novo Nordisk, and AutonomUS Medical Technologies and equity from AutonomUS Medical Technologies. N.O. provides statistical support for two ongoing studies (NIMBLE2 and MASHTrack) funded by the Foundation for the National Institutes of Health (FNIH) through a contract with her institution. She also provides statistical support for EchoSens through a separate contract with her institution. In both cases, no payments are made directly to her. A.A. discloses consultancy to Medscape, Chronic Liver Disease Foundation, and Galectin. A.A. also discloses the Advisory Board role to Novo Nordisk. A.J.S. owns stock options in Tiziana, Rivus, Northsea, consults for Intercept, Genfit, Boehringer Ingelhiem, Eli Lilly, Merck, Amgen, Novo Nordisk, Genentech, Alnylam, Regeneron, Takeda, Glaxo Smith Kline, Roche, Hanmi, LG chem, Astra Zeneca, Zydus, Avant Sante, Histoindex, Path AI, Surrozen, Pliant, Madrigal, Akero, Boston Pharma, 89Bio, has received grants from Echosens, Merck, Madrigal, Hanmi, 89Bio, Akero, Boehringer Ingelhiem, Novo Nordisk, and has received royalties from Elsevier and Wolter Kluwers. T.T.P. has received research support from GE Healthcare, United Imaging, the US Department of Defense, US Food and Drug Administration, Foundation for the National Institutes of Health, the National Institutes of Health, Society of Abdominal Radiology, American Roentgen Ray Society, and Massachusetts General Hospital through his institution to support ongoing research projects. T.T.P. also discloses relationships with Elsevier Inc. (royalties), AutonomUS Medical Technologies Inc. (equity and consultant), Novo Nordisk (consultant), Massachusetts Society of Radiologic Technologists (honoraria), Zhejiang Medical Association (honoraria), Radiological Society of North America (honoraria and travel support), University of Washington (travel support). A.E.S. has received consulting fees from AutonomUS Medical Technologies, Cryosa, Novo Nordisk, Omnizare, Quantonation, Resolve Stroke S.A., Thinksono, and Vortex Imaging. A.E.S. serves as an advisor or has served on advisory or scientific boards for the American Institute of Ultrasound in Medicine, the Foundation for the National Institutes of Health, Ochre Bio, Resolve Stroke, Rhino Federated Computing, Thinksono, and Vortex Imaging. A.E.S. has received institutional research support (equipment, supplies, or other in-kind contributions) from Canon, Echosens, GE HealthCare, Philips, Siemens, Supersonic Imagine, Terason, and United Imaging. A.E.S. has received institutional research funding from the Foundation for the National Institutes of Health, Fujifilm, GE HealthCare, and United Imaging. A.E.S. holds equity in AutonomUS Medical Technologies, Clearwater Sciences, Evidence Based Psychology, Klea, Ochre Bio, Quantix Bio, Rhino Federated Computing, Thinksono, and Vortex Imaging.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8862"}}